A STUDY OF LIQUID CERTOLIZUMAB PEGOL AS ADDITIONAL MEDICATION TO METHOTREXATE IN THE TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND IN PREVENTION OF JOINT DAMAGE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: